Burns, Death, Sepsis, Septic Shock
Conditions
Brief summary
The investigators will compare the efficacy of Interleukin-6 (IL-6) as a better indicator than procalcitonin in burn patients with sepsis or septic shock regarding success of treatment and early ICU discharge.
Detailed description
Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10. Treatment plan will be initiated to all patients according to the burn ICU protocol. According to the lab results, interleukin 6 and procalcitonin will guide the investigators to take decisions regarding clinical improvement and ICU stay.
Interventions
DIAGNOSTIC_TESTInterleukin 6
Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10
Sponsors
Ain Shams University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients with acute burn admitted to burn ICU within 24 hours from the burn incidence. * patients with burn percentage of 25% to 50% of total body surface area * patients with second to third degree burns * ASA 1 and ASA 2 patients
Exclusion criteria
* Burn percentage more than 50% or less than 25% of total body surface area * Having autoimmune diseases * Cancer patients * ASA 3 and ASA 4 patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of sepsis and septic shock | From day 1 to day 10 in burn ICU | Prediction of occurrence of sepsis and septic shock |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Length of ICU stay | One month after ICU admission | Response to treatment and length of ICU stay for over one month |
Countries
Egypt
Contacts
Primary ContactAhmed H Elsayed, M.B.B.CH
Outcome results
None listed